{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:47:25Z","timestamp":1766508445347,"version":"3.48.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Known predictors of recurrence and survival include the total number of nodes and positive nodes resected, tumor stage, histology, and tumor differentiation. Patients with a complete response have the best survival, but residual tumor in the esophagus, nodes, or both may influence survival. This study assesses the risk of recurrence and survival of esophageal adenocarcinoma after trimodal therapy based upon the location residual disease in the resected specimen. Multicenter, retrospective study of patients with esophageal adenocarcinoma undergoing induction chemoradiation and transthoracic esophagectomy from 2010 to 2017. Overall survival (OS) and recurrence were compared based on the residual disease location using Kaplan\u2013Meier analysis. Clinical factors associated with OS and time to recurrence were also assessed. There were 504 patients with a median follow-up of 63.4\u00a0months 95% confidence interval (CI):60.8\u201370.5 and an estimated overall 5-year survival of 55.8%. When subdivided by residual disease location, the estimated 5-year survival in patients with complete pathologic response and residual disease of only the esophagus was 68.3% and 65.0% hazard ratio (HR)\u2009=\u20091.05; P\u2009=\u20090.81. With increasing nodal positivity there was decreasing survival, 45.8% (N1) and 20.1% (N2). N3 patients did not survive past 36\u00a0months.<\/jats:p>\n                  <jats:p>Multivariable analysis demonstrates that any residual disease in the lymph nodes (HR\u2009=\u20093.14), taxane and fluoropyrimidine chemotherapy (HR\u2009=\u20093.34), neoadjuvant radiation dose &amp;lt;50 Gy (HR\u2009=\u20092.35), and fluoropyrimidine chemotherapy (HR\u2009=\u20091.88) were predictive of worse OS. Overall survival and recurrence are influenced by the location of residual disease. Residual disease in the esophagus and pathologic complete response behaves similarly. Survival is reduced as nodal counts increase.<\/jats:p>","DOI":"10.1093\/dote\/doaf125","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:59:15Z","timestamp":1765285155000},"source":"Crossref","is-referenced-by-count":0,"title":["The location and degree of residual disease determines recurrence patterns and survival in patients with esophageal adenocarcinoma after trimodal therapy"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3709-6838","authenticated-orcid":false,"given":"Weston G","family":"Andrews","sequence":"first","affiliation":[{"name":"Department of Surgery, Swedish Cancer Institute , Seattle , Washington,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Blitz","sequence":"additional","affiliation":[{"name":"Sandra Blitz Biostatistical Consulting Services , Kelowna , British Columbia,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5425-2188","authenticated-orcid":false,"given":"Marisa","family":"Sewell","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan-Kettering Cancer Center , New York City, New York,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Molena","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan-Kettering Cancer Center , New York City, New York,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne L","family":"Hofstetter","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center , Houston , Texas,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5759-3028","authenticated-orcid":false,"given":"Jonathan","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail E","family":"Darling","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sharata","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Oregon Clinic , Portland, Oregon ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R","family":"DeMeester","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Oregon Clinic , Portland, Oregon ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G","family":"Peyre","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Southern California , Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Lipham","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Southern California , Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J","family":"Bograd","sequence":"additional","affiliation":[{"name":"Department of Surgery, Swedish Cancer Institute , Seattle , Washington,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T","family":"White","sequence":"additional","affiliation":[{"name":"Department of Surgery, Swedish Cancer Institute , Seattle , Washington,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S","family":"Farivar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Swedish Cancer Institute , Seattle , Washington,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-1000","authenticated-orcid":false,"given":"Brian E","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Surgery, Swedish Cancer Institute , Seattle , Washington,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2025122310175348700_ref1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.09.136","article-title":"Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery","volume":"157","author":"Barbetta","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025122310175348700_ref2","doi-asserted-by":"crossref","first-page":"20410","DOI":"10.18632\/oncotarget.14669","article-title":"Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a metaanalysis based on random clinical trials","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2025122310175348700_ref3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis","volume":"8","author":"Gebski","year":"2007","journal-title":"Lancet Oncol"},{"key":"2025122310175348700_ref4","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"2025122310175348700_ref5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/SLA.0000000000002670","article-title":"Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes","volume":"269","author":"Xi","year":"2019","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref6","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/SLA.0b013e3181904f3c","article-title":"Predicting systemic disease in patients with esophageal cancer after esophagectomy a multinational study on the significance of the number of involved lymph nodes","volume":"248","author":"Peyre","year":"2008","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1442-2050.2001.00164.x","article-title":"Two-field dissection is enough for esophageal cancer","volume":"14","author":"Law","year":"2001","journal-title":"Dis Esophagus"},{"key":"2025122310175348700_ref8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1245\/s10434-019-07870-2","article-title":"How many nodes need to be removed to make esophagectomy an adequate cancer operation, and does the number change when a patient has chemoradiotherapy before surgery?","volume":"27","author":"Yeung","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2025122310175348700_ref9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cncr.21693","article-title":"The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation","volume":"106","author":"Gu","year":"2006","journal-title":"Cancer"},{"key":"2025122310175348700_ref10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2006.07.039","article-title":"The prognostic importance of the number of involved lymph nodes in esophageal cancer","volume":"132","author":"Rizk","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025122310175348700_ref11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtcvs.2009.07.069","article-title":"Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?","volume":"138","author":"Meguid","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025122310175348700_ref12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/SLA.0b013e3182a196f4","article-title":"The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma","volume":"258","author":"Francis","year":"2013","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/SLA.0000000000004638","article-title":"Survival after trimodality therapy in patients with locally advanced esophagogastric adenocarcinoma: does only a complete pathologic response matter?","volume":"276","author":"Sihag","year":"2022","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref14","volume-title":"Esophageal and Esophagogastric Junction Cancers v. 2.2022","author":"NCCN Guidelines Panel","year":"2022"},{"key":"2025122310175348700_ref15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.xjon.2020.12.001","article-title":"Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma","volume":"5","author":"Kandilis","year":"2021","journal-title":"JTCVS Open"},{"issue":"6","key":"2025122310175348700_ref16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","article-title":"Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer","volume":"273","author":"Urakawa","year":"2021","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/SLA.0b013e31817bbe59","article-title":"Total number of resected lymph nodes predicts survival in esophageal cancer","volume":"248","author":"Altorki","year":"2008","journal-title":"Ann Surg"},{"key":"2025122310175348700_ref18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"2025122310175348700_ref19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"2025122310175348700_ref20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"2025122310175348700_ref21","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1097\/AS9.0000000000000497","article-title":"Adjuvant therapy after esophagectomy for esophageal cancer: who needs it?: multi-institution worldwide observational study","volume":"5","author":"Raja","year":"2024","journal-title":"Ann Surg Open"},{"key":"2025122310175348700_ref22","first-page":"1943","volume-title":"Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma","author":"McKay","year":"2024"},{"key":"2025122310175348700_ref23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.athoracsur.2018.09.064","article-title":"Induction radiation therapy for esophageal cancer: does dose affect outcomes?","volume":"107","author":"Semenkovich","year":"2019","journal-title":"Ann Thorac Surg,"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/6\/doaf125\/66117446\/doaf125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/38\/6\/doaf125\/66117446\/doaf125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:21:38Z","timestamp":1766503298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaf125\/8403041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaf125","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,1]]},"article-number":"doaf125"}}